200 related articles for article (PubMed ID: 26677895)
1. Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics.
El-Say KM; Ahmed TA; Abdelbary MF; Ali BE; Aljaeid BM; Zidan AS
Acta Pharm; 2015 Dec; 65(4):365-82. PubMed ID: 26677895
[TBL] [Abstract][Full Text] [Related]
2. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation.
Rahman Z; Zidan AS; Khan MA
Int J Pharm; 2010 Nov; 400(1-2):49-58. PubMed ID: 20801200
[TBL] [Abstract][Full Text] [Related]
3. Effect of disintegrants on the properties of multiparticulate tablets comprising starch pellets and excipient granules.
Mehta S; De Beer T; Remon JP; Vervaet C
Int J Pharm; 2012 Jan; 422(1-2):310-7. PubMed ID: 22101283
[TBL] [Abstract][Full Text] [Related]
4. Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression.
Olmez SS; Vural I; Sahin S; Ertugrul A; Capan Y
Pharmazie; 2013 Feb; 68(2):110-6. PubMed ID: 23469682
[TBL] [Abstract][Full Text] [Related]
5. A new formulation for orally disintegrating tablets using a suspension spray-coating method.
Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825
[TBL] [Abstract][Full Text] [Related]
6. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
7. IDENTIFICATION OF PHARMACEUTICAL EXCIPIENT BEHAVIOR OF CHICKPEA (CICER ARIETINUM) STARCH IN GLICLAZIDE IMMEDIATE RELEASE TABLETS.
Meka VS; Yee P; Sheshala R
Acta Pol Pharm; 2016; 73(2):469-78. PubMed ID: 27180440
[TBL] [Abstract][Full Text] [Related]
8. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation.
Rahman Z; Siddiqui A; Khan MA
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1300-9. PubMed ID: 23800704
[TBL] [Abstract][Full Text] [Related]
9. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
Rasool BK; Fahmy SA; Galeel OW
Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of coprocessed disintegrants produced from tapioca starch and mannitol in orally disintegrating paracetamol tablet.
Adeoye O; Alebiowu G
Acta Pol Pharm; 2014; 71(5):803-11. PubMed ID: 25362809
[TBL] [Abstract][Full Text] [Related]
11. Further improvement of orally disintegrating tablets using micronized ethylcellulose.
Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
Int J Pharm; 2012 Feb; 423(2):351-9. PubMed ID: 22138608
[TBL] [Abstract][Full Text] [Related]
12. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
Hobbs D; Karagianis J; Treuer T; Raskin J
Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
Kokott M; Lura A; Breitkreutz J; Wiedey R
Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
[TBL] [Abstract][Full Text] [Related]
14. Orally disintegrating mini-tablets (ODMTs)--a novel solid oral dosage form for paediatric use.
Stoltenberg I; Breitkreutz J
Eur J Pharm Biopharm; 2011 Aug; 78(3):462-9. PubMed ID: 21324357
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of swelling induced-orally disintegrating tablets by microwave irradiation.
Sano S; Iwao Y; Kimura S; Itai S
Int J Pharm; 2011 Sep; 416(1):252-9. PubMed ID: 21763765
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of fast-dissolving tablets of meloxicam-β-cyclodextrin complex prepared by direct compression.
Obaidat AA; Obaidat RM
Acta Pharm; 2011 Mar; 61(1):83-91. PubMed ID: 21406346
[TBL] [Abstract][Full Text] [Related]
17. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets.
Morott JT; Pimparade M; Park JB; Worley CP; Majumdar S; Lian Z; Pinto E; Bi Y; Durig T; Repka MA
J Pharm Sci; 2015 Jan; 104(1):124-34. PubMed ID: 25410968
[TBL] [Abstract][Full Text] [Related]
18. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
Mostafa HF; Ibrahim MA; Sakr A
Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
[TBL] [Abstract][Full Text] [Related]
19. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets.
Pabari RM; Ramtoola Z
Int J Pharm; 2012 Jul; 430(1-2):18-25. PubMed ID: 22465631
[TBL] [Abstract][Full Text] [Related]
20. Characterization, optimisation and process robustness of a co-processed mannitol for the development of orally disintegrating tablets.
Soh JL; Grachet M; Whitlock M; Lukas T
Pharm Dev Technol; 2013 Feb; 18(1):172-85. PubMed ID: 22582882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
